Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - decitabine - powder for solution for infusion - 50mg

Израиль - английский - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - concentrate for solution for infusion - posaconazole 300 mg/vial - posaconazole - noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults :- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate f

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - ceftazidime pentahydrate; avibactam sodium - powder for solution for infusion - 2gram ; 500mg

Сингапур - английский - HSA (Health Sciences Authority)

pfizer private limited - gemtuzumab ozogamicin - powder, for solution - gemtuzumab ozogamicin 5.0 mg/vial

Ирландия - английский - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - feiba - powder and solvent for solution for infusion - 50 unit(s)/millilitre - blood coagulation factors; factor viii inhibitor bypassing activity - blood coagulation factors - it is used for: treatment of bleeding in hemophilia a patients with inhibitors; treatment of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available (see section 5.1); treatment of bleeding in non-hemophiliacs with acquired inhibitors to factor viii; prophylaxis of bleeding in hemophilia a patients with inhibitors who have experienced a significant bleed or are at high risk of significant bleeding

Ирландия - английский - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - feiba - powder and solvent for solution for infusion - 25 unit(s)/millilitre - blood coagulation factors; factor viii inhibitor bypassing activity - coagulation factors - it is used for: treatment of bleeding in hemophilia a patients with inhibitors; treatment of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available (see section 5.1); treatment of bleeding in non-hemophiliacs with acquired inhibitors to factor viii; prophylaxis of bleeding in hemophilia a patients with inhibitors who have experienced a significant bleed or are at high risk of significant bleeding

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - pemetrexed disodium - powder for solution for infusion - 100mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - pemetrexed disodium - powder for solution for infusion - 500mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram